A Study of Distal Jejunal-release Dextrose in Obese Participants

StatusActive, Not Recruiting

PhasePhase 2

StartedNov 1, 2022

Record status

This record was last updated October 16, 2024 (before its estimated November 11, 2024 completion). Its status may not reflect the trial's current state.

Record History

Notable Oct 14, 2024 Primary and study completion dates: Mar 30, 2024 to Nov 11, 2024
- Start date: Jul 1, 2022 to Nov 1, 2022
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 3 to 9
v4
Minor Jan 11, 2023 Re-verified, no change to tracked fieldsv3
Notable Jan 10, 2023 Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Jul 30, 2023 to Mar 30, 2024
- Study sites: 0 to 3
v2
Minor May 20, 2022 Study First Submitted

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Aphaia Pharma US LLC

2 trials monitored

See all monitored trials

Obesity

3,874 trials monitored

See 152 trials at risk

Hypertension

1,925 trials monitored

See 99 trials at risk

NASH / MASH

687 trials monitored

See 22 trials at risk

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in obese participants.

Trial Details

NCT Number	NCT05385978
Lead Sponsor	Aphaia Pharma US LLC
Conditions (from sponsor)	Obese
Related terms	Endocrine System Diseases, Hypertension, Non-alcoholic Fatty Liver Disease, Obesity
Enrollment	150 participants
Start Date	Nov 1, 2022
Primary Completion	Nov 11, 2024 (estimated)
Study Completion	Nov 11, 2024 (estimated)
Updated on ClinicalTrials.gov	Oct 16, 2024